Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Economic effect of VTB's digital transformation was about ₽300 billion

4/13/23 VTBR

TCS Group created a leasing company

4/13/23 T

Yandex will launch food delivery in Moscow and St. Petersburg under the brand name Market 15

4/13/23 YNDX

The Fastenal announced a quarterly dividend

4/13/23 FAST

Novatek increased LNG sales on international markets by 60%

4/12/23 NVTK

Caterpillar announced a quarterly dividend

4/12/23 CAT

Qualcomm announced a quarterly dividend

4/12/23 QCOM

Board of Directors of Sovcomflot recommended that dividends be paid for 2022

4/12/23 FLOT

Chizhik entered the market of the Republic of Tatarstan

4/12/23 FIVE

KGC reported for 2022 according to RAS

4/12/23 KGKC